Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.42 |
| ▸ | ALPG | P10696 | 2/20 | 0.41 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23203814 | 0.85 | KCNH2 (0.40) | KCNH2ALPGPLAAALPLTLR8 | |
| SCHEMBL8958681 | 0.85 | ALPG (0.42) | KCNH2ALPGPLAAALPLGAA | |
| SCHEMBL10147185 | 0.85 | KCNH2 (0.45) | KCNH2BRD4GAATLR8ALDH1A1 | |
| SCHEMBL24023977 | 0.85 | HTR2A (0.41) | KCNH2ALPGPLAAALPLTLR8 | |
| SCHEMBL15969910 | 0.84 | BRD4 (0.41) | KCNH2BRD4GAATLR8ALDH1A1 | |
| Water SCHEMBL9893341 | 0.82 | BRD4 (0.40) | KCNH2BRD4GAATLR8ALDH1A1 | |
| SCHEMBL5656262 | 0.82 | KCNH2 (0.41) | KCNH2BRD4GAAALDH1A1POLB | |
| SCHEMBL27670108 | 0.82 | BRD4 (0.40) | KCNH2BRD4GAAPOLBKMT2A | |
| SCHEMBL15740501 | 0.82 | KCNH2 (0.47) | KCNH2BRD4GAATLR8ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5657547 | 0.81 | BRD4 (0.39) | KCNH2BRD4GAATLR8POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012130803-A1 | METHOD FOR SEPARATING OFF HALOGENS FROM MIXTURES OF MATTER | BAYER TECHNOLOGY SERVICES GMBH (DE) | 2012-10-04 | — | — | WO | claimed |
| JP-4794561-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| EP-1789160-A1 | METHOD FOR SEPARATING HYDROGEN CHLORIDE AND PHOSGENE | BASF AKTIENGESELLSCHAFT (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006029788-A1 | METHOD FOR SEPARATING HYDROGEN CHLORIDE AND PHOSGENE | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-23 | — | — | WO | claimed |
| US-20210353610-A1 | SMALL MOLECULE MENIN INHIBITORS | SERVIER PHARMACEUTICALS LLC | 2021-11-18 | — | — | US | disclosed |
| US-11045448-B2 | Piperidines as covalent menin inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210115018-A1 | PIPERIDINE COMPOUNDS AS COVALENT MENIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-04-22 | — | — | US | disclosed |
| WO-2021067215-A1 | PIPERIDINE COMPOUNDS AS MENIN INHIBITORS | AGIOS PHARMACEUTICALS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020072391-A1 | SMALL MOLECULE MENIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-04-09 | — | — | WO | disclosed |
| US-10370340-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-9981919-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICAL N.V. (BE) | 2018-05-29 | — | — | US | disclosed |
| US-9981919-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICAL N.V. (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | HEERES JAN | 2007-01-25 | — | — | US | disclosed |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | HEERES JAN | 2007-01-25 | — | — | US | disclosed |
| CN-1897948-A | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2007-01-17 | — | — | CN | disclosed |
| EP-0718288-B1 | Liquid hydrophobic salts, their preparation and their use in electrochemistry | HYDRO QUEBEC (CA) | 2005-06-29 | — | — | EP | disclosed |
| CN-1061038-C | Hydrophobic liquid salts, preparation thereof and their application in electrochemistry | ASULAB SA (CH) | 2001-01-24 | — | — | CN | disclosed |
| US-5683832-A | PHOTOVOLTAIC CELLS | ASULAB S.A. (CH) | 1997-11-04 | — | — | US | disclosed |
| CN-1132746-A | Hydrophobic liquid salts, preparation thereof and their application in electrochemistry | ASULAB SA (CH) | 1996-10-09 | — | — | CN | disclosed |
| EP-0718288-A1 | Liquid hydrophobic salts, their preparation and their use in electrochemistry | ASULAB S.A. (CH) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353610-A1 | SMALL MOLECULE MENIN INHIBITORS | MEN1, BRCA1, KRAS | KCNH2 3041/4885ALPG 2385/4885PLAA 3739/4885 |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | ADORA2B, CYP1B1, DPYD | KCNH2 2031/4885ALPG 4644/4885PLAA 2568/4885 |
| US-20210115018-A1 | PIPERIDINE COMPOUNDS AS COVALENT MENIN INHIBITORS | MEN1, BRCA1, PRMT1 | KCNH2 1984/4885ALPG 3936/4885PLAA 2144/4885 |
| US-11045448-B2 | Piperidines as covalent menin inhibitors | MEN1, H1-10, HDAC10 | KCNH2 1232/4885ALPG 4004/4885PLAA 2517/4885 |
| US-10370340-B2 | HIV replication inhibiting pyrimidines | RRM2B, CCNO, RRM2 | KCNH2 1547/4885ALPG 4874/4885PLAA 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.